Single Subject Neratinib in Bladder Cancer (NRR)

N/ANo Longer AvailableNCT01956253

UNC Lineberger Comprehensive Cancer Center

Overview

This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.

Study Type

EXPANDED_ACCESS

Conditions

Bladder Cancer

Interventions

NeratinibDRUG

240 mg orally once daily

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \* none Exclusion Criteria: \* none We have received FDA approval for a single subject Investigational New Drug (IND) Application to treat a specific patient with the HER2 kinase inhibitor neratinib. Therefore there is no inclusion / exclusion criteria.

Locations (1)

North Carolina Cancer Hospital (UNC)

Chapel Hill, North Carolina, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.